Microbial Cell Factories

Research

Production of surfactin from Bacillus subtilis MZ-7 grown on pharmamedia commercial medium

Muaaz Mutaz Al-Ajlani, Muhammad Abid Sheikh, Zeeshan Ahmad and Shahida Hasnain*

Address: Department of Microbiology and Molecular Genetics, University of the Punjab, Quaid-e- Azam Campus. Lahore, Pakistan

Email: Muaaz Mutaz Al-Ajlani - muaaz01@hotmail.com; Muhammad Abid Sheikh - toofani2003@yahoo.co.in; Zeeshan Ahmad - genekhial@gmail.com; Shahida Hasnain* - genetic@brain.net.pk

* Corresponding author

Published: 5 June 2007

Microbial Cell Factories 2007, 6:17 doi:10.1186/1475-2859-6-17

Received: 23 January 2007
Accepted: 5 June 2007

This article is available from: http://www.microbialcellfactories.com/content/6/1/17

© 2007 Al-Ajlani et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Commercial medium (Pharmamedia) was investigated for the production of surfactin by Bacillus subtilis MZ-7. Different media (defined, semi-defined, and complex media) were compared for the production of surfactin after fixing the least influential variables in standardized fermentation conditions. Carbohydrate and nitrogen supplements were also tried to improve production in Pharmamedia.

Results: Surfactin production was confirmed using PCR along with other analytical techniques and monitored by RP-HPLC and MALDI-TOF-MS. We found that optimized and brain heart infusion media were best for production of surfactin (280 mg/L) and a relatively comparable production with Pharmamedia (220 mg/L), however, supplementing Pharmamedia with Fe⁺ (4.0 mM) and sucrose (2 g/L) leads to a maximum production of about (300 mg/L).

Conclusion: Cottonseed-derived medium proved to be a suitable substrate for the production of bioactive substances including surfactin, a useful compound in both medical and biotechnological fields. The medium provided not only higher product accumulations but at considerably lower cost with potential for large scale industrial applications.

1. Background

Bacillus subtilis strains produce a broad spectrum of bioactive peptides with great potential for biotechnological and biopharmaceutical applications. A well-known class of such compounds includes the lipopeptides surfactin [1-3], fengycin [4], and the iturin compounds [5] iturin A, B, and C [6], mycosubtilins [7], and bacillomycins [8], which are amphiphilic membrane-active biosurfactants and peptide antibiotics with potent antimicrobial activities. Although surfactin was discovered four decades ago, there has been a revival of interest, triggered by increasing evidence for their medical effectiveness [9,10]. Surfactin possessed antimicrobial [11-13], antiviral [14-16], antitumor [17], hemolytic [18], blood anticoagulant, and fibrinolytic [19,18] activities. As one of the strongest biosurfactants [20,21], surfactin has numerous environmental and biotechnological applications [22] and has shown particular utility in oil recovery [23,24], remediation of soil contaminated by heavy metals [25,26], and biocontrol against phytopathogens [27,28] and insects [29]. Diverse new properties have been recognized, including emulsification, foaming [30], inhibition of star-
fish oocyte maturation [31], and antimycoplasmic activities [32].

Despite many advantages of surfactins over chemical agents and great recent advances in our understanding of surfactins [33-37], there have been hardly any significant applications of surfactins, mainly because of low strain productivity and the need for expensive substrates [38,39]. Efforts must therefore be redirected to improve production efficiency and recovery bioprocesses in order to optimize yields [38]. An earlier study carried out using nutrient broth gave a very low yield (100 mg/L) [3]. A minimal mineral salts medium was later defined, containing NH$_4$NO$_3$ (0.05 M) as the inorganic nitrogen source and glucose (4%) as the carbon source (Cooper’s medium; [40]). Other studies have used a semisynthetic medium (Landy’s medium; [41]) that contains L-glutamic acid (5 g/L) as the organic nitrogen source, glucose (2%) as the carbon source, and trace metals [42,43], in one case supplemented with 0.1% yeast extract and 2 mg/l phenylalanine [15]. Optimizing the mineral requirement was particularly beneficiary for the production of surfactin [44,45,40]. Finally, potential substrates for surfactant production have been sought that might provide cheaper and renewable sources for economical production [38,46]. Interesting cheap sources have been described from agroindustrial crops and residues, such as cassava [47], soybean, sugar beet, potato [48,49], and sweet sorghum, from crop residues such as bran and straw of wheat and rice, and from waste derived from oil processing mills, for example soy molasses from soybean processing and the crude glycerol fraction from biodiesel production [50]. There have been no detailed reports concerning other potentially economical substrates, most notably renewable resources, such as vegetable oils, distillery and dairy wastes [51].

In this report, we describe surfactin production by two producer strains and one non-producer strain of *Bacillus subtilis* in synthetic medium and cottonseed-derived medium (Pharmamedia) and demonstrate the potential of the latter to give similar yields as more expensive media.

2. Materials and methods

2.1 Microorganisms

*B. subtilis* MZ-7 [52] is an environmental isolate (the sequence of its 16S rRNA is found in accession no. [DQ327713]). *B. subtilis* ATCC 21332 [3] and *B. subtilis* subsp. *subtilis* 168 [53] are surfactin and non-surfactin producers, respectively [54]. The later strain acted as a negative control in all experiments. *Bacillus fusiformis* NRS 6137 was regularly used as a test organism. All strains except strain MZ-7 were obtained from the Bacillus Genetic Stock Center, Ohio, USA.

2.2. Media and culture condition

Pharmamedia (Traders Protein, USA) is an economical, finely ground, yellow flour made from the embryo of cottonseed. Its detail composition as provided by the manufacturer is listed in Table 1. Landy medium [41], Cooper’s medium [40], optimized medium [55], modified Landy medium [55], and minimal salt medium [56] were made as previously described. Sugars (2 g/L) and nitrogen supplements (3 g/L) were made to the control medium. In all cases, pre-inoculum was prepared by suspending in 10 ml deionized water colonies taken from minimal salt agar. The suspensions were adjusted to 5 × 10$^{12}$ cells per ml. Growth temperature and pH values were maintained at 35°C and 7 ± 0.5, respectively. Fermentation was carried out for 24 or 48 hours in 250 ml conical flasks containing 50 ± 5 ml broth on an orbital shaker operating at 120 rev/min.

2.3. Growth measurement

Measurements of colony forming units were used to monitor the time course of growth in culture, as the suspended insoluble material in Pharmamedia made optical density and dry weight measurements inconvenient. In comparative experiments, cultures were passed through filter paper to collect insoluble large particles and the filtrates were passed through washed and preweighed micropore filters (0.2 μm). The cell-loaded filters were dried at 105°C and reweighed to determine the weights contributed by the cell masses. The values were calibrated by the dry weight of insoluble substances (such as iron sulfate) in fresh (noninoculated) media. However, interference by concentrated iron salts on the measurement of cell dry weight was negligible.

2.4. Detection and sequencing of sfp gene

A 675-bp fragment from the gene (*sfp*) from *B. subtilis* encoding 4'-phosphopantetheinyl transferase [57], corresponding positions 167–841 (GenBank accession no. [X63158]), was targeted for amplification using two oligonucleotides: P17 (5’-ATG AAG ATT TAC GGA ATT TA-3’) and P18 (5’-TTA TAA AAG CTC TTA GCT CTG CG-3’). Amplification was accomplished in a thermal cycler (Mastercycler, Eppendorf, Germany) set for denaturing at 94°C for 1 min, annealing at 46°C for 30 s, and extension at 72°C for 1 min, for a total of 25 cycles. PCR products were analyzed by 1.5% agarose gel electrophoresis. The purified PCR products were sequenced by using an ABI Prism dye terminator cycle sequencing ready reaction kit and an ABI PRISM 377 DNA sequencer (Applied Biosystems, USA). Analyses of DNA sequences were performed by using Prochromas version software (Oxford Molecular, UK).
2.5 Quantification and Qualification Analysis

2.5.1 Isolation of Surfactin

Crude surfactin was isolated by adding concentrated hydrochloric acid to the broth after removing the biomass by centrifugation. A precipitate was formed at pH 2 which was collected, dried, and extracted with dichloromethane. The solvent was removed under reduced pressure to give an off-white solid. Further purification was achieved by recrystallization. The dichloromethane extract was dissolved in distilled water containing sufficient NaOH to produce a pH of 8. This solution was filtered through Whatman filter paper No. 1 and titrated to pH 2 with concentrated HCl. The white solid was collected as a pellet after centrifugation. Samples were scratched out from a
nonsprayed thin layer chromatography (TLC) plate extracted three times with methanol, and reduced by vacuum oven to a volume of 1 ml.

2.5.2 Quantitative analysis of surfactin by HPLC
Active fractions from TLC were further purified by reversed-phase HPLC, using a Thermo Hypersil-Keystone ODS (particle size, 5 μm; column dimensions, 250 by 4.6 mm; Thermo Hypersil, USA). A sample was applied with eluent A (0.1% (vol/vol) trifluoroacetic acid and 20% (vol/vol) acetonitrile) and eluted with segmented gradients of eluent B (0.1% (vol/vol) trifluoroacetic acid and 80% (vol/vol) acetonitrile) as follows: 40% eluent B for 30 min and 40 to 100% eluent B for 10 min. Eluents A and B were made using Milli-Q HPLC grade water. The concentration of surfactin was determined from a calibration curve made by correlating the emulsification index (E) with known amounts of surfactin produced by B. subtilis ATCC 21332.

2.5.3. MALDI-TOF-mass spectrometry
Fractions correlated with surfactin from TLC and Reverse phase HPLC were analyzed using MALDI-TOF-MS. 2 μL of samples were mixed on the target plate with 2 μL of matrix solution (2 mg of alpha-hydroxycinnaminic acid per ml in acetonitrile-methanol-water, 1:1:1). MALDI-TOF-MS spectra were recorded by using a 337-nm nitrogen laser for desorption and ionization. The mass spectrometer was operated in the refraction mode at an accelerating voltage of 18 kV with an ion flight path of 0.7 m. The delay time was 375 ns. Matrix-suppression was also used, and the mass spectra were averaged over 50 to 100 individual laser shots. The laser intensity was set just above the threshold for ion production. External calibration was performed by using the [M+H]+ signals of renin, adeno-corticotropic hormone, insulin oxidized B, and bovine insulin (Sigma-Aldrich Co.). Surfactin isomers were anticipated to have an m/z range of 500–1500. The variance of the m/z of ± 0.8 Da was considered acceptable.

2.6. Statistical analysis
The data is presented in terms of arithmetic averages of at least three replicates, and the error bars indicate the standard deviations. The analyses were carried out using SPSS software, version 14.0 (SPSS Inc., Chicago, USA).

3. Results

3.1. Isolation and quantification of surfactin
The concentrated extracts run on silica TLC plates showed six bands under UV light, having Rf values of 0.1, 0.15, 0.26, 0.37, 0.51 and 0.57. However, a plate bioassay showed two active fractions, those with Rf values of 0.37 and 0.51. The spot with an Rf value of 0.51 was ninhydrin-negative and positive to 4,4’-bis(dimethylamino)diphenylmethane (TDM) reagent. These results indicated the absence of free amino groups and the presence of peptide bonds in the compound. A white spot formed with the same Rf value when the plate was sprayed with water, indicating that the compound is lipophilic. The migration and chemical properties of the compound were comparable to surfactin produced by B. subtilis strain ATCC 21332. We observed that the environmental isolate B. subtilis MZ-7 produced more surfactin (170.5 mg/L) than did B. subtilis ATCC 21332 (109.5 mg/L) under the same conditions.

3.2. Detection of surfactin production by PCR
B. subtilis subsp. subtilis 168 was negative to specific primers for sfp genes. However, 675-bp fragments were amplified with genomic DNA of B. subtilis MZ-7 and B. subtilis ATCC 21332 (Figure 1B). Sequence comparisons showed 99% similarity between these fragments and sfp genes in the database from known surfactin producers [58].

3.3. Confirmation of surfactin by MALDI-TOF-MS
Running MALDI-TOF-MS in refractron mode, we observed a cluster of peaks with mass/charge (m/z) ratios between 1036 and 1058, which could be attributed to protonated surfactin isoforms (Figure 1A). The peak with a m/z ratio 1045.86 corresponds to the mass of [M+Na]+ ion of surfactin with a fatty acid chain length of 14 carbon atoms [59]. Observed isomers of surfactin in different media fermentations were more or less similar [60].

3.4. Standardization of optimal conditions for surfactin production
Figure 2 shows the relationship in Landy medium and Pharmamedia between the density of B. subtilis MZ-7 cultures and the pH of medium and shows the concentration of an antimicrobial compound that appeared over the time course of the incubation. In Landy medium, the concentration of the inhibitory compound was high at 24 h, when the culture was in its post-exponential phase, and reached its highest level at 44 h, i.e. at stationary phase. However, in Pharmamedia, maximum concentration was observed during the post-exponential phase (28 h), with a decrease in production during the stationary phase of the growth cycle. The optimum production time thus differs in Landy medium and Pharmamedia. The pH of culture was almost stable, ranging from 7 to 8.

3.5. Comparative production in different media
Among the laboratory media tested (Figure 3), B. subtilis MZ-7 produced maximum surfactin in BHI and optimized medium (260 mg/L), followed by Landy medium (240 mg/L). Relatively low yields (220 mg/L) were observed in commercial medium (Pharmamedia) without any supplementation. Addition of various carbon and nitrogen sources were tested (Figure 4). It was observed that sucrose supplementation caused a marked enhancement in surfactin production (280 mg/L), potentially significant with
regards to the goal of large scale production of surfactin on cheap media.

4. Discussion
Since its discovery, surfactin has proved to be an interesting biochemical tool for basic research. On account of its biodegradability and its broad range of functional properties, it is now evident that surfactin has potential applications in industrial processes, primarily those involving surfactant activities. Thus, the interest of researchers is warranted but, to date, surfactin has not been able to compete economically with its chemically synthesized counterparts because of poor strain productivity and the need for expensive substrates. Efforts must therefore be redirected to improve the production efficiency and recovery bioprocesses in order to optimize yields. Most nutritional and production studies have been done with batch cultures, usually in shake flasks, but occasionally in small-scale or large-scale fermentors [40,61-63]. A laboratory-scale cyclone column fermentor was used for continuous, phased growth with feedback control, based on the concentration of dissolved oxygen [64,65]. Saccharose and fructose have also been mentioned as efficient carbon sources, while the presence of glycerol greatly decreased surfactin production [66]. In contrast to the biosynthesis of other biosurfactants, surfactin biosynthesis was not stimulated by hexadecane [40,43].

No notable difference in the ability of different amino acids to support surfactin production has been found, yields being 600–800 mg L⁻¹ [43]. When they are used as the sole nitrogen source of a culture medium, some hydrophobic amino acids insert themselves directly into selected positions of the peptide sequence, thus amplifying the original structural microheterogeneity via the production of variants [67].

In contrast to many secondary metabolites of bacilli, the production of which is induced when the cells have exhausted one or more essential nutrients, surfactin production is induced in actively growing cells by progression to postexponential phase [11]. In most of the available literature a combination of nutritional and physicochemical factors giving the highest yields was selected for use. However, the use of effective commercial media was completely neglected until the last decades, when several scientists showed interest in using more economical, renewable sources for production [38,46]. In fact, cottonseed media have been reported to be cost-effective in the production of several antibiotics and enzymes. The per-
formed experiments in this report were conducted in very...
Supplements (St-7)

| Supplements                  | Zone of inhibition (cm) |
|------------------------------|-------------------------|
| Control                      | 0                       |
| Sucrose                      | 0.5                     |
| Mannitol                     | 1.0                     |
| Fructose                     | 1.5                     |
| Glucose                      | 2.0                     |
| Casen Hydrolysate            | 2.5                     |
| Glutamine                    |                         |
| Glycine                      |                         |
| Cysteine                     |                         |
| CaCO3                        |                         |
| Yeast Extract                |                         |
| Tryptone                     |                         |

**Figure 4**
Influence of different supplements on the production of inhibitory substances (Surfactin) in comparison to non-supplemented media (control).

restricted conditions in favor of reproducibility and that is to demonstrate a successful comparison not enhanced production potential. As this paper did not show economical studies, it was left for industrial economists to establish such a relation.

**Authors' contributions**
Al-Ajani carried out this research as part of his PhD work, Sheikh and Ahmad assisted in practical work and Hasnain has supervised the study.

**Acknowledgements**
We thank Prof. D. Garozzo Italy, for MALDI-TOF-MS of prepared samples, Prof. H. Laatsch, Germany for useful discussion and Dr. J. Elhai, USA for English editing.

**References**

1. Hosono K, Suzuki H: Acylpeptides, the inhibitors of cyclic adenosine 3',5'-monophosphate phosphodiesterase. 1. Purification, physicochemical properties and structures of fatty acid residues.  J Antibiot (Tokyo) 1983, 36:667-673.
2. Kakinuma A, Hori M, Isono M, Tamura G, Arima K: Determination of amino acid sequence in surfactin, a crystalline peptide lipid surfactant produced by Bacillus subtilis.  Agric Biol Chem 1969, 33:971-972.
3. Arima K, Kakinuma A, Tamura G: Surfactin, a crystalline peptide lipid surfactant produced by Bacillus subtilis: isolation, characterization and its inhibition of fibrin clot formation.  Biochim Biophys Acta 1968, 131:488-494.
4. Vanitnanon K, Leefler W, Koch U, Jung G: Fengycin-a novel antifungal lipopeptide antibiotic produced by Bacillus subtilis P-29-3.  J Antibiot (Tokyo) 1986, 39:888-901.
5. Besson F, Peyrous F, Michel G, Delcambe L: Identification of antibodies of iturin group in various strains of Bacillus subtilis.  J Antibiot (Tokyo) 1978, 31:284-288.
6. Peyrous F, Guinand M, Michel G, Delcambe L, Das BC, Lederer E: Structure of iturin A, a peptidolipid antibiotic from Bacillus subtilis.  Biochemistry 1978, 17:2992-2996.
7. Peyrous F, Michel G, Delcambe L: Structure of the mycosubtiline, antibiotoque isole de Bacillus subtilis.  European Journal of Biochemistry 1976, 63:391-398.
8. Peyrous F, Pommier M-T, Das BC, Besson F, Delcambe L, Michel G: Structures of bacillomycin D and bacillomycin L, peptidolipid antibiotics from Bacillus subtilis.  J Antibiot 1994, 47:1600-1604.
9. Rodrigues L, Ibrahim MB, Teixeira J, Oliveira R: Biosurfactants: potential applications in medicine.  J Antimicrob Chemother 2006, 57(4):609-618.
10. Singh P, Camestra SS: Potential applications of microbial surfactants in biomedical sciences.  Trends Biotechnol 2004, 22:142-146.
11. Vater J: Lipopeptides, an attractive class of microbial surfactants.  Progr Colloid Polymer Sci 1986, 72:13-18.
12. Demain AL: The peptidolipids of Bacillus: chemistry, biogenesis, and possible functions.  Bacterial Rev 1977, 41:449-474.
13. Bernheimer AV, Avigad LS: Nature and properties of a cytolytic agent produced by Bacillus subtilis.  J Gen Microbiol 1970, 67:361-369.
14. Kracht M, Kosk H, Ozol M, Kovaii M, Pauli G, Vater J: Antiviral and hemolytic activities of surfactin isoforms and their methyl ester derivatives.  J Antibiot 1999, 52:613-619.
15. Vollenbroich D, Pauli G, Ozol M, Vater J: Antimycoplasmal properties and applications in cell culture of surfactin, a lipopeptide antibiotic from Bacillus subtilis.  Appl Environ Microbiol 1997, 63:44-49.
16. Itokawa H, Miyashita T, Morita H, Takeya K, Hirano T, Homma M, Oka K: Structural and conformational studies of [Ile7] and [Leu7] surfactins from Bacillus subtilis.  Chem Pharm Bull 1994, 42:604-607.
17. Kameda Y, Oira S, Matsui K, Kanatomo S, Hase T: Isolation, physicochemical properties and structures of fatty acid residues.  J Antibiot (Tokyo) 1983, 36:1377-1391.
18. Fengycin-a novel antibiotoque isole de Bacillus subtilis.  J Antibiot (Tokyo) 1983, 36:1377-1391.
19. Von Dohren H, Keller U, Vater J, Zocher R: Multifunctional peptide synthetases.  Chem Rev 1997, 97:2675-2705.
20. Solaiman D: Applications of microbial biosurfactants.  Inform 2005, 16:408-410.
21. Voussof N, Simpson DR, Duncan KE, McInerney MJ, Folsombe M, Fincher T, Knap R: In-situ biosurfactant production by injected Bacillus strains in a limestone petroleum reservoir.  Appl Environ Microbiol 2006, 72:234-245.
22. Schaller KD, Fox SL, Bruhn DF, Noah KA, Bala GA: Characterization of surfactin from Bacillus subtilis for application as an agent for enhanced oil recovery.  Appl Biochem Biotechnol 2004, 113-116:827-836.
23. Mulligan CN: Environmental applications for biosurfactants.  Environ Pollut 2005, 133:183-198.
24. Zouboulis AI, Matis KA, Lazaridis NK, Golyshin PN: The use of biosurfactants in flotation: application for the removal of metal ions.  Minerals Engineering 2003, 16:1231-1236.
25. Bais HP, Fall R, Vivanco JM: Biocontrol of Bacillus subtilis against infection of arabidopsis roots by Pseudomonas syringae is facilitated by biofilm formation and surfactin production.  Plant Physiology 2004, 134:307-319.
26. Ongen M, Jacques P, Toure Y, Destain J, Jabrane A, Thonart P: Role of lipopeptides produced by Bacillus subtilis GA1 in the reduction of grey mould disease caused by Botrytis cinerea on apple.  J Appl Microbiol 2004, 96(5):1151-1160.
27. Asse LK, Deleu M, Arnaud L, Paquot M, Thonart P, Gaspar Ch, Haubruge E: Insecticide activity of surfactins and iturins from a biopoeptide Bacillus subtilis Cohn (S499 strain).  Meded Rijksuniv Gent Fak Landbouwkd Toegep Biol Wet 2002, 67(3):647-655.
30. Razafindralambo H, Popineau Y, Deleu M, Hbid C, Jacques P, Thonart P, Paquot M: Foaming properties of lipopeptides produced by Bacillus licheniformis. J Colloid Interface Sci 1987, 113:37-41.
31. Nakano MM, Marahiel MA, Zuber P: Characterization of a constitutive mycosubtilin overproducing Bacillus subtilis strain and its antagonistic activity. Appl Environ Microbiol 2004, 71:4577-4584.
32. Akpa E, Jacques P, Wathelet B, Paquot M, Fuchs R, Budzikiwicz H, Thonart P: Influence of culture conditions on lipoprotein production by Bacillus subtilis. Appl Biochem Biotechnol 2001, 91:551-561.
33. Gumusoglu D, Ozel M, Vater J, Kamp RM, Pauli G: Rapid Detection and Characterization of Surfactin-Producing Bacillus subtilis and Closely Related Species Based on PCR. Current Microbiol 2004, 49(3):186-191.
34. Husecz E, Burczyk B: Surfactin isoforms from Bacillus coagulans. Z Naturforsch (C) 2006, 61(8-10):727-733.
35. Kowall M, Vater J, Kluge B, Bein T, Franke P, Zieser D: Separation and characterization of surfactin isoforms produced by Bacillus subtilis OKB 105. J Colloid Interface Sci 1998, 204:1-8.
36. Mulligan GN, Gibb BF: Recovery of biosurfactants by ultrafiltration. Biochem Eng J 2006, 2:105-112.
37. Lin SC, Carswell KS, Sharma MM, Georgiou G: Continuous production of the lipopeptide biosurfactant of Bacillus licheniformis JP-2. Appl Microbiol Biotechnol 1994, 41:281-285.
38. Jacques P, Hbid C, Destain J, Razafindralambo H, Paquot M, DePauw E, Thonart P: Optimization of biosurfactant lipoprotein production from Bacillus subtilis S499 by plackett-burman design. Appl Biochem Biotechnol 1999:77-79. 223-233.
39. Sheppard JD, Cooper DG: Development of computerized feedback control for the continuous phasing of Bacillus subtilis. Biotechnol Bioeng 1999, 61:539-545.
40. Yeh M, Wei Y, Chang J: Bioreactor design for enhanced carrier-assisted surfactin production with Bacillus subtilis. Process Biochem 2006, 41:1799-1805.
41. Kao J, Lee C, Oh HM, Katsuragi T, Tani Y: Production and properties of a lipopeptide biosurfactant from Bacillus subtilis C9. J Ferment Bioeng 1997, 84:41-46.
42. Peypoux F, Michel G: Controlled biosynthesis of [Val] and [Leu] surfactins. Microbial Biochem 1992, 36:515-517.

33. Mukherjee S, Das P, Sen R: Molecular mechanism of membrane permeabilization by the peptide antibiotic, surfactin from Bacillus licheniformis. J Chem Technol Biotechnol 2003, 78:191-97.
34. Mulkherjee S, Das P, Sen R: Towards commercial production of microbial surfactants. Trends Biotechnol 2006, 24:509-515.
35. Desai JD, Banat IM: Microbial production of surfactants and their commercial potential. Microbial Mol Biol Rev 1997, 61:67-64.
36. Cooper DG, Macdonald CR, Duff SJ, Koster M: Enhanced production of surfactant from Bacillus subtilis by continuous product removal and metal cation additions. Appl Environ Microbiol 1991, 57:426-68.
37. Landy M, Warren GH, Roseman SB, Collo LG: Bacillocymicin: an antibiotic from Bacillus subtilis active against pathogenic fungi. Proc Soc Exp Biol Med 1948, 67:539-541.
38. Nakano MM, Marahiel MA, Zuber P: Identification of a genetic locus involved in biosynthesis of the lipopeptide antibiotic surfactin in Bacillus subtilis. J Bacteriol 1987, 169:562-568.
39. Sandrin C, Peyrous F, Michel G: Coproduction of surfactant and iturin A, lipopeptides with surfactant and antifungal properties, by Bacillus subtilis. Biotechnol Appl Biochem 1990, 12:370-375.
40. Yang X, Lai C, Chang J: Using Taguchi experimental design methods to optimize trace element composition for enhanced surfactant production by Bacillus subtilis ATCC 21332. Process Biochem 2007, 42:40-45.
41. Wei YH, Wang LF, Chang JS, Kung SS: Identification of induced acidiﬁcation in iron-enriched cultures of Bacillus subtilis during surfactant fermentation. J Biosci Bioeng 2003, 96(2):174-178.
42. Maneerat S: Production of biosurfactants using substrates from renewable-resources. Songklanakarin J Sci Technol 2005, 27:675-683.
43. Nitschke M, Pastore GM: Production and properties of a surfactant obtained from Bacillus subtilis grown on cassava wastewater. Bioresource Technology 2006, 97(2):336-34.
44. Noah KS, Bruhn D, Bala GA: Surfactant Production from Potato Process Effluent by Bacillus subtilis in a Chemostat. Applied biochemistry and biotechnology 2005, 122(1-3):465-474.
45. Thompson TN, Fox SL, Bala GA: Biosurfactants from potato process efﬂuents. Appl Biochem Biotechnol 2000, 84-86:917-930.
46. Salaman D, Ashby RD, Foglia TA: Production of biosurfactants by fermentation of fats, oils and their coproducts. In Handbook of Industrial Biocatalysis Edited by: Hou CT. Boca Raton, FL: Taylor & Francis; 2005:14-14-9.
47. Mulligan GN, Gibb BF: Factors influencing the economics of biosurfactants. In Biosurfactants: Production properties applications. Volume 48. Edited by: Kosaric N. Dekker, New York; 1993:329-371.
48. Al-Aljani MM, Hasanin S: Simple and rapid method for isolation of novel antibiotic from Bacillus subtilis MZ-7. J Liq Chrom related Tech 2006, 29:637-645.